Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Léna · SciRah

Researcher profile · Semantic Scholar

H. Léna

Share profile

H. Léna — researcher profile on SciRah

h-index: 40
Works: 201
Citations: 19K

Most-cited papers

Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel +24 more
2015New England Journal of Medicine8,408 citations Open access
Semantic Scholar
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
F. Barlesi, J. Mazières, J. Merlio, D. Debieuvre +28 more
2016The Lancet923 citations Open access
Semantic Scholar
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
S. Ou, J. Ahn, L. De Petris, R. Govindan +14 more
2016Journal of Clinical Oncology604 citations
Semantic Scholar
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
M. Garassino, B. Cho, Joo-Hang Kim, J. Mazières +14 more
2018The Lancet Oncology525 citations Open access
Semantic Scholar
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
A. D. de Langen, M. Johnson, J. Mazières, A. Dingemans +28 more
2023The Lancet483 citations Open access
Semantic Scholar
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
R. Corre, L. Greillier, H. Le Caer, C. Audigier-Valette +19 more
2016Journal of Clinical Oncology352 citations
Semantic Scholar
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
J. Mazières, G. Zalcman, L. Crinò, P. Biondani +21 more
2015Journal of Clinical Oncology349 citations Open access
Semantic Scholar
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
E. Quoix, H. Léna, G. Losonczy, F. Forget +18 more
2016The Lancet Oncology196 citations
Semantic Scholar
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
M. Chatterjee, D. Turner, E. Felip, H. Léna +19 more
2016Annals of Oncology167 citations Open access
Semantic Scholar
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
N. Baize, I. Monnet, L. Greillier, M. Geier +18 more
2020The Lancet Oncology133 citations Open access
Semantic Scholar
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
P. Ferolla, M. Brizzi, T. Meyer, W. Mansoor +18 more
2017The Lancet Oncology126 citations Open access
Semantic Scholar
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
M. Johnson, Z. Zvirbule, K. Laktionov, Å. Helland +18 more
2021Journal of Thoracic Oncology123 citations Open access
Semantic Scholar
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Claire Merveilleux du Vignaux, É. Dansin, L. Mhanna, L. Greillier +16 more
2018Journal of Thoracic Oncology81 citations Open access
Semantic Scholar
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
J. Yang, S. Ou, L. De Petris, S. Gadgeel +16 more
2017Journal of Thoracic Oncology75 citations Open access
Semantic Scholar
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
N. Guibert, F. Barlesi, R. Descourt, H. Léna +16 more
2017Journal of Thoracic Oncology66 citations Open access
Semantic Scholar
First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
K. Amrane, M. Geier, R. Corre, H. Léna +13 more
2020Cancer Medicine61 citations Open access
Semantic Scholar
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
M. Garassino, B. Cho, Joo-Hang Kim, J. Mazières +14 more
2020Lung Cancer50 citations Open access
Semantic Scholar
PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study
M. Garassino, J. Vansteenkiste, J. H. Kim, H. Léna +6 more
201746 citations Open access
Semantic Scholar
Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.
L. Mezquita, M. Jové, E. Nadal, M. Kfoury +27 more
2020Journal of Thoracic Oncology41 citations Open access
Semantic Scholar
Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer
H. Wakelee, Z. Zvirbule, F. De Braud, Daniel C. Kingsley +12 more
2017Clinical Lung Cancer38 citations
Semantic Scholar
LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
M. Johnson, A. D. de Langen, D. Waterhouse, J. Mazières +16 more
2022Annals of Oncology36 citations Open access
Semantic Scholar
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
C. Basse, S. Thureau, S. Bota, É. Dansin +18 more
2017Journal of Thoracic Oncology36 citations Open access
Semantic Scholar
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
N. Girard, J. Mazières, J. Otto, H. Léna +16 more
2021Annals of Oncology33 citations Open access
Semantic Scholar
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients. Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.
F. Dugay, F. Llamas-Gutiérrez, Marjory Gournay, Sarah Medane +8 more
2017OncoTarget33 citations Open access
Semantic Scholar
Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
S. Ou, J. Ahn, L. De Petris, R. Govindan +14 more
201530 citations
Semantic Scholar
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
H. Léna, I. Monnet, O. Bylicki, C. Audigier-Valette +12 more
2022Journal of Clinical Oncology28 citations
Semantic Scholar
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
L. Gandhi, S. Ou, A. Shaw, F. Barlesi +14 more
2017European Journal of Cancer28 citations
Semantic Scholar
Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study
P. Ferolla, M. Brizzi, T. Meyer, W. Mansoor +12 more
201628 citations Open access
Semantic Scholar
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
S. Ou, S. Gadgeel, F. Barlesi, J. Yang +15 more
2019Lung Cancer26 citations
Semantic Scholar
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
S. Couraud, F. Barlesi, Clara Fontaine-Deraluelle, D. Debieuvre +17 more
2019European Journal of Cancer24 citations
Semantic Scholar
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab
R. Herbst, E. Garon, Dong-Wan Kim, B. Cho +17 more
201723 citations Open access
Semantic Scholar
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
C. Agar, M. Geier, G. Léveiller, R. Lamy +7 more
2020JTO Clinical and Research Reports22 citations Open access
Semantic Scholar
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
J. Bennouna, N. Girard, C. Audigier-Valette, A. Le Thuaut +16 more
2019Clinical Lung Cancer22 citations
Semantic Scholar
An Original Case of an Association of Eosinophilic Fasciitis with Cholangitis Induced by Nivolumab.
E. Le Tallec, C. Ricordel, L. Triquet, A. Deniel +4 more
2019Journal of Thoracic Oncology22 citations Open access
Semantic Scholar
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
B. Besse, J. Mazières, L. Ribassin-Majed, F. Barlesi +17 more
2017Annals of Oncology22 citations Open access
Semantic Scholar
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
P. Fournel, A. Vergnenégre, G. Robinet, H. Léna +86 more
2016European Journal of Cancer22 citations
Semantic Scholar
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
C. Chouaid, T. Filleron, D. Debieuvre, M. Pérol +18 more
2021Targeted oncology21 citations
Semantic Scholar
Systemic Capillary Leak Syndrome (Clarkson's Disease) as a Complication of Anti-Programmed Death 1 Immunotherapy.
C. Lescure, Alain Lescoat, A. Salé, Y. Bazin +3 more
2019Journal of Thoracic Oncology21 citations Open access
Semantic Scholar
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
Guillaume Eberst, A. Anota, A. Scherpereel, J. Mazières +16 more
2019Clinical Cancer Research19 citations Open access
Semantic Scholar
Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small–cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)
C. Chouaid, M. Salaün, V. Gounant, M. Febvre +14 more
2019PLoS ONE19 citations Open access
Semantic Scholar
Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
F. Barlesi, A. Dingemans, C.-H. J. Yang, S. Ou +10 more
201618 citations Open access
Semantic Scholar
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
S. Loubière, A. Drezet, M. Beau-Faller, D. Moro-Sibilot +17 more
2018European Respiratory Journal17 citations Open access
Semantic Scholar
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).
A. Vergnenègre, I. Monnet, A. Bizieux, M. Bernardi +4 more
2020Future Oncology15 citations Open access
Semantic Scholar
Spontaneous splenic rupture as a rare complication of G-CSF injection
S. Benguerfi, F. Thépault, H. Léna, C. Ricordel
2018BMJ Case Reports15 citations Open access
Semantic Scholar
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
C. Raynaud, L. Greillier, J. Mazières, I. Monnet +13 more
2015BMC Cancer15 citations Open access
Semantic Scholar
Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next‐generation Sequencing
C. Ricordel, A. Lespagnol, F. Llamas-Gutiérrez, M. de Tayrac +7 more
2017Clinical Lung Cancer14 citations
Semantic Scholar
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
A. Lavolé, L. Greillier, J. Mazières, I. Monnet +11 more
2020European Respiratory Journal13 citations Open access
Semantic Scholar
Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.
E. Le Tallec, A. Lescoat, A. Ballerie, B. Cador +6 more
2020Journal of Thoracic Oncology13 citations Open access
Semantic Scholar
Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
C. Ricordel, Francesco Llamas Gutierrez, D. Chiforeanu, H. Léna +1 more
2017Journal of Thoracic Oncology13 citations
Semantic Scholar
1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
B. C. Cho, M.-J. Ahn, T. Kim, C. Kim +14 more
2022Annals of Oncology12 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Mazières×17
Invite
J. Mazières — researcher profile on SciRah
F. Barlesi×13
Invite
F. Barlesi — researcher profile on SciRah
I. Monnet×10
Invite
I. Monnet — researcher profile on SciRah
V. Westeel×8
Invite
V. Westeel — researcher profile on SciRah

×8

Invite

É. Dansin — researcher profile on SciRah

Invite

R. Gervais — researcher profile on SciRah

Invite

C. Ricordel — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

C. Audigier-Valette×7

Invite

C. Audigier-Valette — researcher profile on SciRah

Invite

R. Lamy — researcher profile on SciRah

Invite

F. Morin — researcher profile on SciRah

Invite

G. Zalcman — researcher profile on SciRah